Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription 13.06.2022 2 Arch Virol 2 Biochem Biophys Res Commun 1 Biochemistry 1 BMC Pediatr 5 BMJ 1 Epidemiol Infect 1 J Exp Med 5 J Infect Dis 1 J Virol 8 JAMA 5 Lancet 1 MMWR Morb Mortal Wkly Rep 4 N Engl J Med 1 PLoS Biol 1 PLoS Comput Biol 1 PLoS Med 43 PLoS One 23 Vaccine 3 Virology 1 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Arch Virol

1. NGWE TUN MM, Luvai E, Nwe KM, Toume K, et al
   Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro.
   Arch Virol. 2022;167:1547-1557.
   PubMed         Abstract available
   
   
2. BAHLAWAN O, Badra R, Semaan H, Fayad N, et al
   Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon.
   Arch Virol. 2022;167:1509-1519.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

3. MINAGAWA H, Sawa H, Fujita T, Kato S, et al
   A high-affinity aptamer with base-appended base-modified DNA bound to isolated authentic SARS-CoV-2 strains wild-type and B.1.617.2 (delta variant).
   Biochem Biophys Res Commun. 2022;614:207-212.
   PubMed         Abstract available
   
   
4. DUAN L, Yin H, Liu J, Wang W, et al
   Fetal neurodevelopmental spatio-temporal dynamic transcriptional landscape of maternal insult-induce autism spectrum disorder risk.
   Biochem Biophys Res Commun. 2022;614:183-190.
   PubMed         Abstract available
   
   

   
   Biochemistry

5. UPADHYAY V, Patrick C, Lucas A, Mallela KMG, et al
   Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection.
   Biochemistry. 2022;61:963-980.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

6. JAMALI Z, Sinaei R, Estabragh ER, Ahangaran A, et al
   Sigmoid colon perforation in a SARS-CoV-2 positive neonate: a uniqueness report and a brief review.
   BMC Pediatr. 2022;22:327.
   PubMed         Abstract available
   
   

   
   BMJ

7. PHIZACKERLEY D
   Three more points about Paxlovid for covid-19.
   BMJ. 2022;377:o1397.
   PubMed        
   
   
8. DYER O
   Covid-19: Doctor who sold hydroxychloroquine as "magic bullet" treatment is jailed.
   BMJ. 2022;377:o1395.
   PubMed        
   
   
9. WISE J
   Private cancer provider collapses despite drive to tackle NHS backlog.
   BMJ. 2022;377:o1401.
   PubMed        
   
   
10. STOKEL-WALKER C
    How are vaccines being adapted to meet the changing face of SARS-CoV-2?
    BMJ. 2022;377:o1257.
    PubMed        
    
    
11. WISE J
    Covid-19: Two million people in the UK are estimated to be experiencing long covid, says ONS.
    BMJ. 2022;377:o1391.
    PubMed        
    
    

    
    Epidemiol Infect

12. LACY J, Mensah A, Simmons R, Andrews N, et al
    Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England.
    Epidemiol Infect. 2022;150:e109.
    PubMed         Abstract available
    
    

    
    J Exp Med

13. CAMPBELL TM, Liu Z, Zhang Q, Moncada-Velez M, et al
    Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency.
    J Exp Med. 2022;219.
    PubMed         Abstract available
    
    

    
    J Infect Dis

14. KRAYNYAK KA, Blackwood E, Agnes J, Tebas P, et al
    SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
    J Infect Dis. 2022 Jan 25. pii: 6515374. doi: 10.1093.
    PubMed         Abstract available
    
    
15. LAURIE MT, Liu J, Sunshine S, Peng J, et al
    SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron.
    J Infect Dis. 2022;225:1909-1914.
    PubMed         Abstract available
    
    
16. LUCZKOWIAK J, Labiod N, Rivas G, Rolo M, et al
    Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naive and COVID-19 convalescent individuals.
    J Infect Dis. 2021 Dec 28. pii: 6486499. doi: 10.1093.
    PubMed         Abstract available
    
    
17. BRUXVOORT KJ, Ackerson B, Sy LS, Bhavsar A, et al
    Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults.
    J Infect Dis. 2021 Dec 28. pii: 6486498. doi: 10.1093.
    PubMed         Abstract available
    
    
18. VERBURGH ML, Boyd A, Wit FWNM, Schim van der Loeff MF, et al
    Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV.
    J Infect Dis. 2021 Dec 20. pii: 6470931. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

19. SCHEIBNER D, Breithaupt A, Luttermann C, Blaurock C, et al
    Genetic Determinants for Virulence and Transmission of the Panzootic Avian Influenza Virus H5N8 Clade 2.3.4.4 in Pekin Ducks.
    J Virol. 2022 Jun 7:e0014922. doi: 10.1128/jvi.00149.
    PubMed         Abstract available
    
    

    
    JAMA

20. LARKIN HD
    Warning Against Counterfeit At-home COVID-19 Tests.
    JAMA. 2022;327:2067.
    PubMed        
    
    
21. LI Y
    Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave.
    JAMA. 2022;327:2147-2148.
    PubMed        
    
    
22. LATRONICO N, Rasulo FA, Piva S
    Outcomes Among Patients With 1-Year Survival After Intensive Care Unit Treatment for COVID-19.
    JAMA. 2022;327:2149.
    PubMed        
    
    
23. BAI W, Jackson T, Xiang YT
    Outcomes Among Patients With 1-Year Survival After Intensive Care Unit Treatment for COVID-19.
    JAMA. 2022;327:2148-2149.
    PubMed        
    
    
24. SEVIN CM, Ely EW
    Outcomes Among Patients With 1-Year Survival After Intensive Care Unit Treatment for COVID-19.
    JAMA. 2022;327:2149-2150.
    PubMed        
    
    
25. MASLO C, Toubkin M
    Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave-Reply.
    JAMA. 2022;327:2148.
    PubMed        
    
    
26. HEESAKKERS H, van den Boogaard M, Zegers M
    Outcomes Among Patients With 1-Year Survival After Intensive Care Unit Treatment for COVID-19-Reply.
    JAMA. 2022;327:2150-2151.
    PubMed        
    
    
27. ALHAZZANI W, Parhar KKS, Weatherald J, Al Duhailib Z, et al
    Effect of Awake Prone Positioning on Endotracheal Intubation in Patients With COVID-19 and Acute Respiratory Failure: A Randomized Clinical Trial.
    JAMA. 2022 May 15. pii: 2792506. doi: 10.1001/jama.2022.7993.
    PubMed         Abstract available
    
    

    
    Lancet

28. HARTERT TV, Ortiz JR
    Need for improved global measurement of early childhood respiratory syncytial virus disease.
    Lancet. 2022;399:1993-1995.
    PubMed        
    
    
29. LI Y, Wang X, Blau DM, Caballero MT, et al
    Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
    Lancet. 2022;399:2047-2064.
    PubMed         Abstract available
    
    
30. CLARK H, Cardenas M, Dybul M, Kazatchkine M, et al
    Transforming or tinkering: the world remains unprepared for the next pandemic threat.
    Lancet. 2022;399:1995-1999.
    PubMed        
    
    
31. KICKBUSCH I, Liu A
    Global health diplomacy-reconstructing power and governance.
    Lancet. 2022 May 17. pii: S0140-6736(22)00583.
    PubMed         Abstract available
    
    
32. ZHANG X, Zhang W, Chen S
    Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic.
    Lancet. 2022 May 6. pii: S0140-6736(22)00838.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

33. WARD LA, Black KP, Britton CL, Tompkins ML, et al
    COVID-19 Cases, Hospitalizations, and Deaths Among American Indian or Alaska Native Persons - Alaska, 2020-2021.
    MMWR Morb Mortal Wkly Rep. 2022;71:730-733.
    PubMed         Abstract available
    
    

    
    N Engl J Med

34. RUBIN EJ, Baden LR, Moore PL, Morrissey S, et al
    Audio Interview: Dissecting the Host Response to SARS-CoV-2.
    N Engl J Med. 2022;386:e69.
    PubMed        
    
    
35. HAGER KJ, Perez Marc G, Gobeil P, Diaz RS, et al
    Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2201300.
    PubMed         Abstract available
    
    
36. DAI L, Gao L, Tao L, Hadinegoro SR, et al
    Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2202261.
    PubMed         Abstract available
    
    
37. NOHYNEK H, Wilder-Smith A
    Does the World Still Need New Covid-19 Vaccines?
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMe2204695.
    PubMed        
    
    

    
    PLoS Biol

38. FOLARIN RO, Maina MB, Akinbo AK, Runsewe-Abiodun TI, et al
    Bypassing shortages of personal protective equipment in low-income settings using local production and open source tools.
    PLoS Biol. 2022;20:e3001658.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

39. GOZZI N, Chinazzi M, Davis JT, Mu K, et al
    Anatomy of the first six months of COVID-19 vaccination campaign in Italy.
    PLoS Comput Biol. 2022;18:e1010146.
    PubMed         Abstract available
    
    

    
    PLoS Med

40. MACHADO DB, Williamson E, Pescarini JM, Alves FJO, et al
    Relationship between the Bolsa Familia national cash transfer programme and suicide incidence in Brazil: A quasi-experimental study.
    PLoS Med. 2022;19:e1004000.
    PubMed         Abstract available
    
    

    
    PLoS One

41. DEBELE T, Teshome F, Amdisa D, Bacha G, et al
    A mixed-methods study on health learning materials utilization for COVID-19 risk communication and community engagement among health workers in Arsi Zone, Ethiopia: Implication for response to pandemic.
    PLoS One. 2022;17:e0269574.
    PubMed         Abstract available
    
    
42. HENNEBERG M, Zadzinska E
    Auxology of small samples: A method to describe child growth when restrictions prevent surveys.
    PLoS One. 2022;17:e0269420.
    PubMed         Abstract available
    
    
43. FULK A, Romero-Alvarez D, Abu-Saymeh Q, Saint Onge JM, et al
    Using Google Health Trends to investigate COVID-19 incidence in Africa.
    PLoS One. 2022;17:e0269573.
    PubMed         Abstract available
    
    
44. CASTRO-SANGUINETTI GR, Marques Simas PV, Apaza-Chiara AP, Callupe-Leyva JA, et al
    Genetic subtyping and phylogenetic analysis of HA and NA from avian influenza virus in wild birds from Peru reveals unique features among circulating strains in America.
    PLoS One. 2022;17:e0268957.
    PubMed         Abstract available
    
    
45. YOON H, Lee I, Kang H, Kim KS, et al
    Big data-based risk assessment of poultry farms during the 2020/2021 highly pathogenic avian influenza epidemic in Korea.
    PLoS One. 2022;17:e0269311.
    PubMed         Abstract available
    
    
46. AYTON D, Soh SE, Berkovic D, Parker C, et al
    Experiences of personal protective equipment by Australian healthcare workers during the COVID-19 pandemic, 2020: A cross-sectional study.
    PLoS One. 2022;17:e0269484.
    PubMed         Abstract available
    
    
47. ONEN-DUMLU Z, Harper AL, Forte PG, Powell AL, et al
    Optimising the balance of acute and intermediate care capacity for the complex discharge pathway: Computer modelling study during COVID-19 recovery in England.
    PLoS One. 2022;17:e0268837.
    PubMed         Abstract available
    
    
48. JARIYAVAJEE C, Lamjiak T, Ratanasanya S, Fairee S, et al
    Cash stock strategies during regular and COVID-19 periods for bank branches by deep learning.
    PLoS One. 2022;17:e0268753.
    PubMed         Abstract available
    
    
49. ADARYUKOV J, Grunevski S, Reed DD, Pleskac TJ, et al
    I'm wearing a mask, but are they?: Perceptions of self-other differences in COVID-19 health behaviors.
    PLoS One. 2022;17:e0269625.
    PubMed         Abstract available
    
    
50. WIDYAHENING IS, Vidiawati D, Pakasi TA, Soewondo P, et al
    Noncommunicable diseases risk factors and the risk of COVID-19 among university employees in Indonesia.
    PLoS One. 2022;17:e0263146.
    PubMed         Abstract available
    
    
51. BEZUGLOV E, Khaitin V, Lazarev A, Achkasov E, et al
    The incidence and severity of COVID-19 in adult professional soccer players in Russia.
    PLoS One. 2022;17:e0265019.
    PubMed         Abstract available
    
    
52. PROESMANS M, Rector A, Keyaerts E, Vandendijck Y, et al
    Risk factors for disease severity and increased medical resource utilization in respiratory syncytial virus (+) hospitalized children: A descriptive study conducted in four Belgian hospitals.
    PLoS One. 2022;17:e0268532.
    PubMed         Abstract available
    
    
53. LU H, Gan H
    Evaluation and prevention and control measures of urban public transport exposure risk under the influence of COVID-19-Taking Wuhan as an example.
    PLoS One. 2022;17:e0267878.
    PubMed         Abstract available
    
    
54. LIN LY, Mulick A, Mathur R, Smeeth L, et al
    The association between vitamin D status and COVID-19 in England: A cohort study using UK Biobank.
    PLoS One. 2022;17:e0269064.
    PubMed         Abstract available
    
    
55. NEU C, Baumbach P, Scherag A, Kortgen A, et al
    Identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in COVID-19-sepsis (ICROVID): Protocol for a prospective multi-centre cohort study.
    PLoS One. 2022;17:e0269247.
    PubMed         Abstract available
    
    
56. PISCOYA A, Parra Del Riego A, Cerna-Viacava R, Rocco J, et al
    Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0269368.
    PubMed         Abstract available
    
    
57. DHUNGANA GP, Kumar V
    Exponentiated Odd Lomax Exponential distribution with application to COVID-19 death cases of Nepal.
    PLoS One. 2022;17:e0269450.
    PubMed         Abstract available
    
    
58. VILLA CASTANO LE, Duran WF, Arohuanca Percca PA
    Perception of the quality of remote lessons in the time of COVID-19: A comparative study in Latin America quality of remote lessons in the context of COVID-19.
    PLoS One. 2022;17:e0268966.
    PubMed         Abstract available
    
    
59. WANG W, Lin W, Bao Z, Dai X, et al
    Study on the influence of COVID-19 on the growth of China's small and medium-sized construction enterprises.
    PLoS One. 2022;17:e0266315.
    PubMed         Abstract available
    
    
60. SOE PP, Hnin ZL, Hlaing T, Min H, et al
    Changes in physical activity, dietary and sleeping pattern among the general population in COVID-19: A systematic review protocol.
    PLoS One. 2022;17:e0269202.
    PubMed         Abstract available
    
    
61. ALTWAIJRI Y, Bilal L, Almeharish A, BinMuammar A, et al
    Psychological distress reported by healthcare workers in Saudi Arabia during the COVID-19 pandemic: A cross-sectional study.
    PLoS One. 2022;17:e0268976.
    PubMed         Abstract available
    
    
62. BRITO-COSTA S, Jonason PK, Tosi M, Antunes R, et al
    Opinions and options about COVID-19: Personality correlates and sex differences in two European countries.
    PLoS One. 2022;17:e0268193.
    PubMed         Abstract available
    
    
63. SIMACHEW Y, Ejeso A, Dejene S, Ayalew M, et al
    Knowledge, practice, and impact of COVID-19 on mental health among patients with chronic health conditions at selected hospitals of Sidama regional state, Ethiopia.
    PLoS One. 2022;17:e0269171.
    PubMed         Abstract available
    
    
64. VILLANUEVA P, Wadia U, Crawford NW, Messina NL, et al
    The safety of co-administration of Bacille Calmette-Guerin (BCG) and influenza vaccines.
    PLoS One. 2022;17:e0268042.
    PubMed         Abstract available
    
    
65. MOSE A, Wasie A, Shitu S, Haile K, et al
    Determinants of COVID-19 vaccine acceptance in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0269273.
    PubMed         Abstract available
    
    
66. NAZ-MCLEAN S, Kim A, Zimmer A, Laibinis H, et al
    Feasibility and lessons learned on remote trial implementation from TestBoston, a fully remote, longitudinal, large-scale COVID-19 surveillance study.
    PLoS One. 2022;17:e0269127.
    PubMed         Abstract available
    
    
67. HOUSE RV, Broge TA, Suscovich TJ, Snow DM, et al
    Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics.
    PLoS One. 2022;17:e0267796.
    PubMed         Abstract available
    
    
68. FULIN P, Daniel M, Walder J, Grzelecki D, et al
    Impact of the COVID-19 pandemic on orthopaedic and traumatological care in Prague, the capital of the Czech Republic.
    PLoS One. 2022;17:e0269164.
    PubMed         Abstract available
    
    
69. RAVAGHI H, Naidoo V, Mataria A, Khalil M, et al
    Hospitals early challenges and interventions combatting COVID-19 in the Eastern Mediterranean Region.
    PLoS One. 2022;17:e0268386.
    PubMed         Abstract available
    
    
70. VAN GOETHEM N, Vandromme M, Van Oyen H, Haarhuis F, et al
    Severity of infection with the SARS-CoV-2 B.1.1.7 lineage among hospitalized COVID-19 patients in Belgium.
    PLoS One. 2022;17:e0269138.
    PubMed         Abstract available
    
    
71. GURUNG AB, Ali MA, Lee J, El-Zaidy M, et al
    Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19.
    PLoS One. 2022;17:e0268919.
    PubMed         Abstract available
    
    
72. PAIGE SR, Campbell-Salome G, Alpert J, Markham MJ, et al
    Cancer patients' satisfaction with telehealth during the COVID-19 pandemic.
    PLoS One. 2022;17:e0268913.
    PubMed         Abstract available
    
    
73. SEIDENFELD J, Tupetz A, Fiorino C, Limkakeng A, et al
    Experiences of COVID-19 infection in North Carolina: A qualitative analysis.
    PLoS One. 2022;17:e0269338.
    PubMed         Abstract available
    
    
74. BREETZKE J, Wild EM
    Social connections at work and mental health during the first wave of the COVID-19 pandemic: Evidence from employees in Germany.
    PLoS One. 2022;17:e0264602.
    PubMed         Abstract available
    
    
75. DEPUCCIO MJ, Gaughan AA, Shiu-Yee K, McAlearney AS, et al
    Doctoring from home: Physicians' perspectives on the advantages of remote care delivery during the COVID-19 pandemic.
    PLoS One. 2022;17:e0269264.
    PubMed         Abstract available
    
    
76. SINGH B, Lant S, Cividini S, Cattrall JWS, et al
    Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis.
    PLoS One. 2022;17:e0263595.
    PubMed         Abstract available
    
    
77. FAKHRUDDIN KS, Samaranayake LP, Buranawat B, Ngo H, et al
    Oro-facial mucocutaneous manifestations of Coronavirus Disease-2019 (COVID-19): A systematic review.
    PLoS One. 2022;17:e0265531.
    PubMed         Abstract available
    
    
78. SACRISTAN-GALISTEO C, Del Corral T, Rios-Leon M, Martin-Casas P, et al
    Construct validity of the Spanish version of the Post-COVID-19 Functional Status scale and validation of the web-based form in COVID-19 survivors.
    PLoS One. 2022;17:e0269274.
    PubMed         Abstract available
    
    
79. ROGERS BG, Tao J, Almonte A, Toma E, et al
    Statewide evaluation of COVID-19 vaccine hesitancy in Rhode Island.
    PLoS One. 2022;17:e0268587.
    PubMed         Abstract available
    
    
80. PILTCH-LOEB R, Silver DR, Kim Y, Norris H, et al
    Determinants of the COVID-19 vaccine hesitancy spectrum.
    PLoS One. 2022;17:e0267734.
    PubMed         Abstract available
    
    
81. AHIAKPA JK, Cosmas NT, Anyiam FE, Enalume KO, et al
    COVID-19 vaccines uptake: Public knowledge, awareness, perception and acceptance among adult Africans.
    PLoS One. 2022;17:e0268230.
    PubMed         Abstract available
    
    
82. PABAYO R, Grinshteyn E, Steele B, Cook DM, et al
    The relationship between voting restrictions and COVID-19 case and mortality rates between US counties.
    PLoS One. 2022;17:e0267738.
    PubMed         Abstract available
    
    
83. GRANDJEAN D, Elie C, Gallet C, Julien C, et al
    Diagnostic accuracy of non-invasive detection of SARS-CoV-2 infection by canine olfaction.
    PLoS One. 2022;17:e0268382.
    PubMed         Abstract available
    
    

    
    Vaccine

84. WATANABE A, Nishida S, Burcu T, Shibahara T, et al
    Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-beta-cyclodextrin: A phase 1 clinical trial.
    Vaccine. 2022 Jun 4. pii: S0264-410X(22)00677.
    PubMed         Abstract available
    
    
85. CARSON B, Isaacs J, Carilli T
    Jabbing together? The complementarity between social capital, formal public health rules, and COVID-19 vaccine rates in the United States.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00612.
    PubMed         Abstract available
    
    
86. ROBERTSON DA, Mohr KS, Barjakova M, Lunn PD, et al
    Experimental pre-tests of public health communications on the COVID-19 vaccine: A null finding for medical endorsement, risk and altruism.
    Vaccine. 2022 May 16. pii: S0264-410X(22)00613.
    PubMed         Abstract available
    
    
87. IWATA S, Sonoyama T, Kamitani A, Shibata R, et al
    Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00494.
    PubMed         Abstract available
    
    
88. REICHERZ F, Golding L, Lavoie PM, Abu-Raya B, et al
    Decay of anti-Bordetella pertussis antibodies in women of childbearing age following COVID-19 non-pharmaceutical measures.
    Vaccine. 2022;40:3746-3751.
    PubMed         Abstract available
    
    
89. STEELFISHER GK, Caporello H, McIntosh R, Muhammad Safdar R, et al
    Preventing erosion of oral polio vaccine acceptance: A role for vaccinator visits and social norms.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00567.
    PubMed         Abstract available
    
    
90. FREW PM, Gonzalez-Casanova I, Otieno NA, Malik FA, et al
    Development of effective messages to promote maternal immunization in Kenya.
    Vaccine. 2022;40:3761-3770.
    PubMed         Abstract available
    
    
91. ALYA WA, Maraqa B, Nazzal Z, Odeh M, et al
    COVID-19 vaccine uptake and its associated factors among Palestinian healthcare workers: Expectations beaten by reality.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00610.
    PubMed         Abstract available
    
    
92. FEIKIN DR, Abu-Raddad LJ, Andrews N, Davies MA, et al
    Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00523.
    PubMed         Abstract available
    
    
93. SCHENK J, Abrams S, Litzroth A, Cornelissen L, et al
    Identifying immunity gaps for measles using Belgian serial serology data.
    Vaccine. 2022;40:3676-3683.
    PubMed         Abstract available
    
    
94. DE-LOS-RIOS-PINTO A, Fernandez-Guzman D, Soriano-Moreno DR, Sangster-Carrasco L, et al
    Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00421.
    PubMed         Abstract available
    
    
95. TEASDALE CA, Ratzan S, Stuart Lathan H, Rauh L, et al
    Acceptability of COVID-19 vaccine mandates among New York City parents, November 2021.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00580.
    PubMed         Abstract available
    
    
96. KUMAR SURI R, Hayman B, Prasad SD, Makhoana M, et al
    Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00576.
    PubMed         Abstract available
    
    
97. DUC DANG A, Dinh Vu T, Hai Vu H, Thanh Ta V, et al
    Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00526.
    PubMed         Abstract available
    
    
98. RUSKIN AC, Rice S, O'Connor M, Ruskin KJ, et al
    Effects of vaccination status in the United States on willingness to undergo surgery during a pandemic: A prospective survey study.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00583.
    PubMed         Abstract available
    
    
99. MANCARELLA M, Natarelli F, Bertolini C, Zagari A, et al
    Catch-up vaccination campaign in children between 6 and 8 years old during COVID-19 pandemic: The experience in a COVID hub in Milan, Italy.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00573.
    PubMed         Abstract available
    
    
100. YI S, Choe YJ, Lim DS, Lee HR, et al
     Impact of national Covid-19 vaccination Campaign, South Korea.
     Vaccine. 2022 May 8. pii: S0264-410X(22)00572.
     PubMed         Abstract available
     
     
101. POLLET J, Strych U, Chen WH, Versteeg L, et al
     Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
     Vaccine. 2022;40:3655-3663.
     PubMed         Abstract available
     
     
102. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
     Covid-19 vaccine immunogenicity in people living with HIV-1.
     Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
     PubMed         Abstract available
     
     
103. EVANS S, Holt D, Weil-Olivier C, Finnegan G, et al
     Building population and health system resilience: Using lessons learned during the COVID pandemic to implement life-course immunisation policy.
     Vaccine. 2022;40:3511-3513.
     PubMed        
     
     
104. WILLIAMS E, Craig K, Chiu C, Davies H, et al
     Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.
     Vaccine. 2022;40:3484-3489.
     PubMed         Abstract available
     
     
105. SPARROW E, Adetifa I, Chaiyakunapruk N, Cherian T, et al
     WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
     Vaccine. 2022;40:3506-3510.
     PubMed         Abstract available
     
     
106. EVANS B, Jombart T
     Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic.
     Vaccine. 2022;40:3531-3535.
     PubMed         Abstract available
     
     

     
     Virology

107. KUMAR P, Mathayan M, Smieszek SP, Przychodzen BP, et al
     Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection.
     Virology. 2022;572:64-71.
     PubMed         Abstract available
     
     
108. PONDE RAA
     Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern.
     Virology. 2022;572:44-54.
     PubMed         Abstract available
     
     
109. KHAN K, Khan SA, Jalal K, Ul-Haq Z, et al
     Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant.
     Virology. 2022;572:28-43.
     PubMed         Abstract available
     
     

     
     Virus Res

110. FAYAD N, Habib WA, El-Shesheny R, Kandeil A, et al
     Lebanese SARS-CoV-2 genomics: 24 months of the pandemic.
     Virus Res. 2022;317:198824.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: